Healthcare News and Analysis Roundup

Readings for the past few days ...

Liz Moyles - with her very comprehensive SPOOKTAKULAR roundup

Bryn Davies - Medtech Roundup with news on Proximie Olympus Corporation Distalmotion and Smith+Nephew

Speaking of Distalmotion , Joe Mullings interviews CEO Greg Roche on their platform #Dexter receiving FDA clearance

Simon Jenkinson covers Ozempic from the podcast of Acquired , BRI vs BMI, and wearable neurotech from his weekly picks of content

Ann M. Richardson, MBA on upcoding at UVA

Frank Kumli - reviews what the future may hold in Hospital at Home

Andrew Roberts tradeoff of rising healthcare costs - employers respond with salary adjustments or headcount reductions

Scott Fulton - bending the Opportunity Curve - very insightful article

Bertalan Meskó, MD, PhD - so many posts to choose. Here are two on diabetes and the technologies shaping the future of pharma ?

Dutch Rojas reviews the relation of health systems and insurance carriers work inflating costs and prices which are passed along through higher premiums?here

GLP-1 News

?Weight-Loss Drugs Nor Bariatric Surgery Curb Health Costs Within 2 Years - Reuters

Chris Deacon 's shares her always insightful views on the Reuter's story of weight-loss drugs not curbing health costs in this post

Bariatric Surgery News Related to GLP-1

With more than a 2-fold increase in use of GLP-1 RAs as antiobesity medications from 2022 to 2023, there has been a 25.6% decrease in the rate of metabolic bariatric surgery during the same period from JAMA

Similarly, Sg2 had a forecast on Bariatric back in June– IP bariatric surgery volumes will see a 15% decline in the next decade, fueled in part by scaled adoption of pharmaceuticals coming to market, but also by a shift in commercial and self-paid bariatric surgical volumes shifting to the OP setting, which is projected to see a 13% increase.

According to Department of Surgery, Columbia University and their State of the Union of Weight Loss Surgery, as a result of their popularity (GLP-1), we're seeing a decrease in the number of patients who are seeking bariatric surgery. Nationally, there's a trend of about 10 to 20%, depending on the market decrease in volume in bariatric surgery.?

Real-time Fallout of Bariatric Surgery Declines

GLP-1s spur Oklahoma system to close clinic, end bariatric services

My anecdote of GLP-1 impact - local commercial advertisement for discount in bariatric - sleeve procedure. I believe the procedure average cost is $15,000.

Courtney Younglove, M.D., FOMA, FACOG, DABOM breaks down her perspective on weight loss drugs and bariatric surgery and the relation to inflammation in this insightful commentary

Food and GLP-1s

Great analysis by Ipsos North America on how obesity drugs, politics and climate change are shaping the future of food - What the Future of Food. Thanks to Kristopher Hull for sharing.

More from 益普索 on Global Trends - set some time for this lengthy and in-depth commentary.

Speaking of food, USDA is leaning towards dietary guidelines to recommend more reductions of red meat consumption while pushing for more plant-based diets. The National Cattlemen’s Beef Association (NCBA) is pushing back hard- story here.

Cardiovascular Disease Forecast Sg2

Sg2 sees cardiovascular disease continues to rise due to aging population and obesity in this white paper.

They forecast an +8% increase in demand volume for inpatient cardiovascular and +25% outpatient cardiovascular volume for the 2024 to 2034 time frame.

Sanjeev Valentine provides some hope in future forthcoming medtech developments in this space

#healthcare #medicine #health #future #foodasmedicine #healthyfood #nutrition #healthyeating

Joseph W. Sunderman is an Intelligence Analyst/Strategist that is a student of understanding the Current State of the US Health and its impact for the next decade. I developed the thesis over several months for Directions Research Group, which can be found in my project section of my LinkedIn page.

In the past, Joe spent seven years at medical device giant Ethicon (division of Johnson & Johnson) with the most recent role as US Regional Manager of Strategic Insights and Pricing.? In his seven years at JNJ, he received recognition for his servant leadership, where he was a stand out in performance by being a top 10% recipient of Encore and Inspire Awards over multiple years.? Dozens and dozens of accolades from contributors to senior leaders for his collaborative work.? Prior to Ethicon, Joe has had a wide variety of experiences in medical claims, banking, publishing, and retail.? He began his career at Schaeffer's Investment Research as a financial analyst, where he was ranked by Bridge Information Systems as one of the top 10 market analysts for three straight years for his commentary and stock picks found in Schaeffer's Daily Bulletin. Joe has been published in the Market Pulse Journal and Chartpoint and his market comments have been printed in the USA Today, Wall Street Journal, Barron's, Investor's Business Daily, Dow Jones News Wire, and Reuters. Also, Joe has made appearances on Bloomberg television.